Search | Clinical Trials Finder

Conditions: Depressive Symptoms
Interventions: DepCare, Enhanced Usual Care; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Interventions: TAS6417; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 9
States / cities: Henderson, Nevada • Las Vegas, Nevada • Canton, Ohio + 1 more

Conditions: Sexual Health
Interventions: Ashwagandha, Placebo; Dietary Supplement · Other
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Sleep Disorders, Sleep Apnea, Obstructive, Restless Legs Syndrome, Sleep Disorders, Circadian Rhythm, Sleep Initiation and Maintenance Disorders
Interventions: Sleep Hygiene Education, Expert-Led Sleep Disorders Screening and Treatment, Online Sleep Disorders Screening; Behavioral · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 683 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Huntington's Disease
Interventions: Pridopidine, Placebo; Drug · Other
Lead sponsor: Prilenia; Industry
Eligibility: 21 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 16
States / cities: La Jolla, California • Los Angeles, California • Englewood, Colorado + 12 more

Conditions: Alzheimer Disease, Dementia of Alzheimer Type
Interventions: PET/MR Imaging, 64Cu-FBP8; Diagnostic Test · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 55 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Arthritis, Rheumatoid
Interventions: GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 46
States / cities: Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more

Conditions: Down Syndrome (DS), Keratoconus, Pellucid Marginal Degeneration, Forme Fruste Keratoconus (FFK)
Interventions: Epi-ON corneal cross-linking (CXL); Combination Product
Lead sponsor: Woolfson Eye Institute; Other
Eligibility: 8 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 12
States / cities: Atlanta, Georgia • Canton, Georgia • Cumming, Georgia + 8 more

Conditions: HIV Disease, Bipolar Disorder
Interventions: Psychoeducation, individualized Texting for Adherence Building (iTAB); Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Breast Cancer
Interventions: Docetaxel, PANVAC-V, PANVAC-F, Sargramostim; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 2
States / cities: Bethesda, Maryland • Houston, Texas

Conditions: Substance Use Disorder, Posttraumatic Stress Disorder
Interventions: Prolonged Exposure with Contingency Management, Standard Care; Behavioral
Lead sponsor: UConn Health; Other
Eligibility: 18 Years to 25 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 3
States / cities: Farmington, Connecticut • Hartford, Connecticut • New Britain, Connecticut

Conditions: Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis
Interventions: methotrexate, methotrexate - etanercept - prednisolone arm; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 2 Years to 17 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 15
States / cities: Palo Alto, California • San Diego, California • San Francisco, California + 12 more

Conditions: Metastatic Solid Tumors, Treatment-Refractory Cancers
Interventions: rhIL-15, Ipilimumab, Nivolumab, Tumor biopsies, EKG, ECHO, CT Scan; Drug · Procedure · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Opioid Use Disorder, Treatment Adherence
Interventions: iENDURE; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Cardiovascular Disease
Interventions: oral education & written tips for remembering medications, pill box, pocket medication card, sharing information with community pharmacist, Medication use evaluations by community pharmacist, informing physician if patient has stopped a medication, Routine discharge counseling, Letter to physician/discharge summary; Behavioral · Device · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pancreatic Neuroendocrine Tumor, Pancreas Cancer
Interventions: cytoreductive surgery, Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT), Peptide receptor radionuclide therapy (PRRT); Procedure · Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Rheumatoid Arthritis
Interventions: Filgotinib, Placebo to match filgotinib, csDMARDs; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 55
States / cities: Huntsville, Alabama • Gilbert, Arizona • Covina, California + 52 more

Conditions: Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung, Pulmonary Hypertension, Usual Interstitial Pneumonia
Interventions: Not listed
Lead sponsor: Cosmos Rx, Inc; Industry
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Traumatic Brain Injury, Posttraumatic Stress Disorders, Trauma, Combat Disorders, Pain
Interventions: TMRDU; Device
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Camp Pendleton, California • Tampa, Florida • Fort Knox, Kentucky

Conditions: Progressive Supranuclear Palsy, Dementia With Lewy Bodies, Multiple System Atrophy, Corticobasal Syndrome, Atypical Parkinson Disease
Interventions: Home Visit Program, Usual Care/Online Survey; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 40 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pain, Sickle Cell Disorder
Interventions: Normal saline, Ketamine; Drug
Lead sponsor: Billy Sin; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Hypoactive Sexual Desire Disorder, Sexual Dysfunctions, Psychological
Interventions: Ginkgo Biloba, Sex Therapy (genital focus); Drug · Behavioral
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 65 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Opioid Use Disorders
Interventions: CAM2038 SC injection, SL BPN/NX tabs, placebo SC injections, SL placebo tablets; Drug
Lead sponsor: Braeburn Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 36
States / cities: Birmingham, Alabama • Haleyville, Alabama • Hamilton, Alabama + 32 more

Conditions: ERα+ Breast Cancer, ESR1 Gene Mutation
Interventions: Tamoxifen, FES PET/CT; Drug · Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 19 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Madison, Wisconsin

Search by objective public record fields.

Implementation Science Approach to Enhancing Depression Treatment in Collaborative Depression Care Settings ( DepCare )

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

Effects of Ashwagandha Extract (Capsule KSM-66 300 mg) on Sexual Health in Healthy Women

Comprehensive Police Fatigue Management Program

A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

Assess Fibrin in Brains With AD/ADRD

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome

Texting to Improve Adherence in HIV+ With Bipolar Disorder

Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer

Integrated Treatment for Posttraumatic Stress Disorder and Substance Abuse in Young Adults

Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Digital Health Intervention to Support Opioid Use Disorder Treatment

Study of an Intervention to Improve Use of Life-saving Medications for Heart Disease

Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension

Telepharmacy Robotic Medicine Delivery Unit "TRMDU" Assessment

In-Home Care for Patients With PSP and Related Disorders

Ketamine Infusion for Acute Sickle Cell Crisis in the Emergency Department

Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction

Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence

FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer